Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention

Choongseob Oh¹, Soonyong Park¹, Eun Kyung Lee² & Yung Joon Yoo¹

¹School of Life Sciences, Gwangju Institute of Science & Technology (GIST), Gwangju 500-712, Republic of Korea, ²Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea.

Ubiquitin is involved in almost every cellular process, and it is also known to be a stress-inducible protein. Based on previous reports that many types of cancer display an elevated level of ubiquitin, we hypothesized that this increased amount of ubiquitin is essential for the growth of cancer cells and that, consequently, the downregulation of ubiquitin may be a potential anti-cancer treatment. We first found that the level of ubiquitin can be effectively downregulated via knockdown of a polyubiquitin gene, Ubb, with siRNA (Ubb-KD) and then demonstrated its anti-cancer effects in several cancer cell lines and xenograft mice. Ubb-KD resulted in the attenuation of TNFα-induced NF-κB activation, the stabilization of the tumor suppressor p53, and stress-sensitization. Taken together, downregulation of ubiquitin through Ubb-KD is a potential anti-cancer treatment by inhibiting ubiquitination at multiple sites related to oncogenic pathways and by weakening the ability of cancer cells to overcome increased stress.

Ubiquitin (Ub) is a small eukaryotic protein that is covalently attached to proteins by the consecutive actions of three distinct enzymes. Ub is first activated by a Ub-activating enzyme (E1), transferred to a Ub-conjugating enzyme (E2), and then attached to a target protein under the control of a Ub ligase (E3). There are only a few E1 enzymes, ~30 E2s, and over 600 E3s in humans, which together generate a variety of different ubiquitinated forms of many thousands of proteins by single or multiple site monoubiquitination as well as by polyubiquitinations of different lengths and topologies. A variety of ubiquitinated products are then specifically recognized either by Ub receptors containing Ub-binding domains (UBD), leading to downstream effects, or by deubiquitinating enzymes, which catalyze the reverse reaction. Thus, the Ub system is extremely versatile and can play multiple essential roles in various cellular processes by regulating not only protein stability but also protein interactions, trafficking, and activation.

Therefore, it is not surprising that alterations in the Ub system have been observed in many types of human cancers and that many of its components, when deregulated, have been found to play key roles in cellular processes relevant to tumorigenesis. Due to, in part, the success of the proteasome inhibitor bortezomib, the various upstream components of the Ub system are currently under investigation or in clinical study for the development of new anti-cancer therapies. These studies now encompass almost every step of the Ub system, including not only the proteasome but also E1-E2-E3 cascade enzymes, Ub receptors, and deubiquitinating enzymes.

We are particularly interested in the elevated level of Ub that has been observed in most, if not all, cancer cells. In addition, a positive relationship between Ub levels and the progression of hepatocellular carcinoma has been reported. Ub exists in cells either free or covalently conjugated to various intracellular proteins. Free Ub must be provided in a timely manner and in an adequate amount for conjugation to a variety of proteins; it is either continuously supplied for housekeeping functions, such as protein homeostasis, including the removal of misfolded or damaged proteins, or transiently supplied for signaling pathways upon a signaling cue, such as the TNFα-activated NF-κB pathway. Therefore, elevated Ub levels in cancer cells imply that the housekeeping function is overactive and/or that certain ubiquitination-mediated signaling pathways are chronically hyperactive. In addition, given that cancers exhibit various stress phenotypes, including proteotoxic stress, and that Ub itself is a stress-inducible protein, increased Ub is likely to support the ability of cancer cells to overcome escalating cellular stresses.

In this study, we hypothesized that an elevated Ub level during tumorigenesis becomes essential and is maintained for the survival and proliferation of the cancer cells; thus, the downregulation of Ub levels would
be preferentially detrimental to cancer cells. Here, we demonstrated that Ub levels are efficiently reduced by knockdown of the polyUb gene Ubb (Ubb-KD) with small interfering RNA (siRNA), which effectively inhibited the survival and proliferation of cancer cells. Although the detailed molecular mechanism is not clear, we identified multiple potential mechanisms for the anti-cancer effects induced by limiting the supply of Ub via Ubb-KD, including delay of NF-κB activation, inhibition of cell cycle progression, and stabilization of the tumor suppressor p53. Taken together, our data strongly suggest that the downregulation of Ub by Ubb-KD has potential as a new therapeutic intervention for cancer treatment.

Results

Downregulation of Ub by knockdown of the polyUb gene Ubb.

First, we attempted to downregulate the level of Ub by blocking the de novo synthesis of Ub. Four different genes encode Ub in humans: Rps27a, Uba52, Ubb, and Ubc (Fig. 1a). Among them, the polyUb genes Ubb and Ubc, which encode 3 and 9 tandem Ubs, respectively, were targeted for knockdown. Ubb and Ubc were chosen because Rps27a and Uba52 are thought to be essential for protein synthesis because they encode fusion proteins of Ub with the ribosomal subunits of S27a and L40, respectively. When 20 nM of siRNA targeting the mRNA from the Ubb gene (Ubb-siRNA) was transfected into SH-SYSY human neuroblastoma cells, Ubb mRNA was almost completely degraded in 48 h, while the expression of other Ub genes was not affected (Fig. 1b). Specific degradation of Ubb mRNA by the treatment of Ubb siRNA was further confirmed by quantitative real-time PCR (Supplementary Fig. 1). By contrast, transfection with siRNA against Ubc mRNA resulted in incomplete degradation of Ubc mRNA and substantial degradation of Rps27a mRNA (data not shown). In cells, Ub is either free or covalently conjugated to many different intracellular proteins. When the Ub level was assessed by anti-Ub immunoblot after SDS-PAGE, both mono-Ub and conjugated Ub levels decreased in a dose-dependent manner upon treatment with 5 nM, 10 nM and 20 nM Ubb siRNA (Fig. 1c). Because mono-Ub and conjugated Ub cannot be quantitatively compared in an anti-Ub immunoblot, we independently compared each amount by densitometry and found that mono-Ub showed a larger decrease (Fig. 1d). For example, Ubb-KD with 20 nM Ubb siRNA resulted in a greater than 70% decrease in the mono-Ub level, whereas there was less than a 30% decrease in the level of conjugated Ub (Fig. 1d).

Figure 1 | Ub levels are downregulated by the knockdown of Ubb mRNA with siRNA. (a) Schematic representation of the 4 Ub genes; Rps27a and Uba52 encode Ub as a fusion protein with the ribosomal subunits S27a and L40, respectively, whereas Ubb and Ubc encode tandem units of Ub with 3 and 9 repeats, respectively. All Ub gene products are known to be processed co-translationally. (b) SH-SYSY neuroblastoma cells were transfected with 20 nM control siRNA or Ubb siRNA for 48 h, and the mRNA level of each Ub gene was analyzed by PCR. Ubb siRNA effectively and specifically depleted Ubb mRNA. β-actin mRNA was used as a control. (c) SH-SYSY cells were transfected with different concentrations of Ubb siRNA (5, 10, and 20 nM) for 48 h, and the Ub level was analyzed by Western blotting following SDS-PAGE of whole protein extracts. A mono-Ub (mUb) can be resolved from conjugated Ub appeared as smear and several discrete bands including ubiquitinated histone (arrow). (d) The amounts of mono-Ub and conjugated Ub were independently compared by densitometry (n = 2). Both decreased in a dose-dependent manner, but the downregulation of mono-Ub was particularly noticeable. The data are shown as the mean ± SD, #, p < 0.1; *, p < 0.05; **, p < 0.01.
Mono-Ub under reducing conditions includes not only free mono-Ub but also Ub thioester linked to enzymes, which can be separated by NR/R-2DE. During NR/R-2DE, the thioester bonds (denoted by ~) are maintained under non-reducing conditions in the first dimensional separation but are easily cleaved under the reducing conditions of the second dimensional separation, so that thioester-linked Ubs are detached from enzymes and migrate independently. In addition to free mono-Ub, a total of 5 discrete mono-Ub spots were detected by anti-Ub immunoblotting after NR/R-2DE: one spot from E1~Ub and 4 spots from E2~Ub (Supplementary Fig. 2). Densitometric analyses of these mono-Ub spots from HEK293 cells treated with 10 nM control siRNA or Ubb siRNA revealed that free mono-Ub and all 5 mono-Ub spots originated from thioester-linked Ub, were decreased by approximately 50% (Supplementary Figs. 2b and 2c). Consistent with these results, the amount of Ub-linked enzyme, for example, Ube2K/UBE2K−Ub, was similarly reduced by treatment with Ubb siRNA (Supplementary Fig. 2d). Thus, the downregulation of de novo Ub synthesis by Ubb siRNA decreased the amount of free mono-Ub and, in turn, the level of Ub-charged enzymes, thereby resulting in a reduced supply of Ub for conjugation.

**Ubb-KD inhibits cell proliferation and induces apoptotic cell death in cultured cancer cells.** We next investigated whether Ubb-KD could inhibit cell proliferation as expected. When SH-SYSY cells were transfected with 20 nM Ubb siRNA and cultured for 72 h, inhibition of cell proliferation was clearly observed by light microscopy (upper panel in Fig. 2a). MTT assays demonstrated that cell proliferation was inhibited by 55% ± 20% in Ubb siRNA-transfected cells compared with control siRNA-transfected cells (upper panel in Fig. 2b). We also observed that many Ubb siRNA-transfected cells displayed a shrunken shape and detached from the culture plates, suggestive of apoptotic cell death. FACS analyses revealed that 70% ± 16% of Ubb siRNA-transfected cells were apoptotic cells in the sub-G1 population, whereas only 10% ± 0.9% of control siRNA-transfected cells were apoptotic (upper panel in Fig. 2c). This difference in apoptotic cell death was also confirmed by the increased cleavage of PARP in Ubb siRNA-treated cells (Fig. 2c).

The effects of Ubb-KD on cancer cell proliferation and apoptosis were further examined in PC3 prostate cancer cells and HepG2 hepatocellular carcinoma cells. At 72 h after transfection with 20 nM Ubb siRNA, cell proliferation was inhibited by 70% ± 8% in PC3 cells and by 45% ± 20% in HepG2 cells (Figs. 2a and 2b). This treatment also induced apoptotic cell death at 72 h in 43% ± 10% of PC3 cells and 57% ± 10% of HepG2 cells (Fig. 2c). Increased cleavage of PARP was also observed in both Ubb siRNA-treated cell lines (Fig. 2c). In addition to MTT assay, we assessed the effect of Ubb-KD on colony formation ability for 7 days by clonogenic assays and found that the colony forming ability was reduced by the treatment of 20 nM Ubb siRNA to 66.7% ± 3%, and 47 ± 20% for SH-SYSY, PC3, and HepG2 cells, respectively (Supplementary Fig. 3).

Because Ubb-KD induced apoptotic cell death, we also examined its effect on cell cycle progression. SH-SYSY, PC3, and HepG2 cells were transfected with control siRNA or Ubb siRNA, and cell cycle distributions were analyzed at 0 h, 12 h, 24 h, 36 h, and 48 h by FACS (Fig. 2d). In SH-SYSY cells, apoptotic cell death was detected at 48 h without any noticeable G2/M arrest (Fig. 2d). By contrast, the cell population at G2/M phase began increasing before apoptotic cells appeared in PC3 and HepG2 cells (Fig. 2d). Therefore, sequential induction of G2/M arrest and apoptosis after Ubb-KD appears to be cell-type dependent in both PC3 and HepG2 cells but not in SH-SYSY cells.

Given that PARP cleavage increased upon the downregulation of Ub by Ubb-KD, we tested 20 μM zVAD-fmk on those cells and found that the observed cell death was prevented by a caspase inhibitor almost completely in SH-SYSY and HepG2 cells and partially in PC3 cells (Supplementary Fig. 4), implying that cell death by Ubb-KD was dependent on caspases.

Taken all together, the downregulation of Ub level by Ubb-KD effectively inhibited the cell proliferation and induced apoptotic cell death in cancer cells although the efficiency of Ubb-KD and the rate of cell death seemed to be dependent on cancer cell types.

**Ubb-KD is preferentially cytotoxic to MCF7 cancer cells than MCF10A normal cells.** Interestingly, Ubb-KD inhibited the proliferation of MCF7 breast cancer cells to a much greater extent than MCF10A normal breast cells: 38% ± 7% in MCF7 cells compared with 12% ± 2% in MCF10A cells (Figs. 3a and 3b). In addition, Ubb-KD induced increased apoptotic cell death in MCF7 cells compared to MCF10A cells: 31% ± 3% in MCF7 cells compared with 5.6% ± 4.9% in MCF10A cells. Differences in apoptotic cell death were also confirmed by an increased level of cleaved PARP and DNA fragmentation in Ubb siRNA-transfected MCF7 cells compared with MCF10A cells (Figs. 3c and 3d). Our results clearly demonstrated that the downregulation of Ub by Ubb-KD is preferentially more cytotoxic to MCF7 cancer cells than MCF10A normal cells. We further evaluated Ubb-KD on the proliferation of another normal cell. WhenDetroit 551 normal human embryonic skin cells were transfected with 20 nM Ubb siRNA, Ub level was significantly downregulated but there was little effects on cell proliferation (Supplementary Fig. 5), supporting our hypothesis that cancer cells are more reliant on the Ub level than normal cells.

**Ubb-KD inhibits tumor cell growth in a mouse xenograft model.** We further examined the inhibitory effect of Ubb-KD on tumor cell growth in a mouse xenograft model. For this purpose, PC3 cells were first transfected with either control siRNA or Ubb siRNA and then injected subcutaneously into the left and right flanks of nude mice (n = 11). Tumor size was measured every 5 days after injection, and the final tumor mass was weighed on day 40 (Fig. 4). PC3 cell-derived tumor growth was partially blocked by Ubb-KD, resulting in an approximately 40% reduction in both tumor volume and weight (Fig. 4). Given that we employed siRNA to downregulate the Ub level of injecting PC3 cells, Ub level was presumably resumed at the relatively early stage of tumor growth so that 40% reduction in tumor size should be attributed to the initial effect of Ub depletion. Therefore, it was not surprised to observe no difference in Ub level between left and right tumors at day 40 (Supplementary Figs. 6a and 6b). However, reduced Ub level could be observed at least in day 5 tumors derived from PC3 cells with Ubb-KD compared with the control (Supplementary Figs. 6c and 6d).

**Ubb-KD inhibits Ub-dependent protein degradation.** To assess the effect of Ubb-KD on protein degradation, we first analyzed the stability of unstable GFP (GFPu), a test substrate protein for ubiquitination-dependent proteasomal degradation, using SH-SYSY cells stably expressing GFPu, and found that Ubb-KD clearly stabilized GFPu in cells (Fig. 5a). We also analyzed the endogenous cellular proteins and found that the p53 tumor suppressor, a known ubiquitination-dependent proteasomal substrate, was stabilized in Ubb siRNA-transfected cells, whereas ornithine decarboxylase (ODC), a known ubiquitination-independent proteasomal substrate, was not stabilized in the same cells (Fig. 5b). In addition, the α-chain of the T-cell receptor (αTCR), an endoplasmic reticulum-associated degradation (ERAD) substrate, was also stabilized in αTCR-expressing HeLa cells after transfection with Ubb siRNA (Fig. 5c). Taken together, the reduction in Ub levels by Ubb-KD effectively inhibits ubiquitination-dependent proteasomal degradation, presumably via the attenuation of ubiquitination process.

Given that ubiquitination is also involved in the endocytosis and lysosomal degradation of many receptors, we examined the stability of EGFR in Ubb siRNA-transfected HeLa cells after treatment with
EGF. Degradation of the EGFR was significantly delayed by *Ubb*-KD, with an increase in the estimated half-life of EGFR from 30 min to 60 min (Figs. 5d and 5e). Delayed degradation of EGFR in *Ubb*-siRNA-transfected HeLa cells was also observed by immunostaining (Supplementary Fig. 7). At 3 h after treatment with EGF, significant amounts of EGFR were detected in *Ubb*-siRNA-transfected cells, whereas little was observed in control cells (Supplementary Fig. 7).

Interestingly, *Ubb*-KD resulted in an increase in stress-inducible proteins such as HSP70 and GRP78, cytosolic and ER proteins, respectively (Fig. 5f). PCR and real-time PCR revealed that the expression of the corresponding mRNAs was also upregulated.
(Figs. 5g and 5h), implying that Ubb-KD results in stress overload in cancer cells.

**Ubb-KD inhibits TNFα-induced NF-κB activation.** The NF-κB pathway is the major signaling cascade involved in tumor-promoting inflammation, making it an attractive target for cancer therapy. Various cellular stimuli converge on the activation of NF-κB, which then induces the expression of a vast array of proteins, including cytokines, growth factors, and anti-apoptotic proteins. To assess the effect of Ubb-KD on NF-κB activation, we first assessed the TNFα-mediated activation of transcriptional activity in an NF-κB-driven luciferase reporter assay. There was no change in RLU after transfection of Ubb siRNA alone. Upon treatment with 50 ng/ml TNFα for 2 h, RLU increased 23 ± 6.3-fold in control cells but only 6.8 ± 5-fold in Ubb siRNA-transfected cells, corresponding to ~70% inhibition (Fig. 6a).

IkBα is bound to the NF-κB dimer p50/p65 under basal conditions but is rapidly degraded following stimulation, which allows p50/p65 to translocate from the cytoplasm to the nucleus and activate gene expression. Immunostaining of HeLa cells for p65 revealed that p65, which was exclusively located in the cytoplasm, was rapidly translocated into the nucleus in the control cells after treatment with

---

**Figure 3 | Ubb-KD was more cytotoxic to MCF7 than MCF10A cells.** (a) MCF7 and MCF10A cells were transfected with control siRNA or Ubb siRNA (20 nM) for 72 h and then observed by light microscopy. The levels of Ub in the transfected cells were compared by Western blotting with an anti-Ub antibody; α-tubulin was used as a control. (b) Relative cell proliferation was measured by MTT assay (n = 5). (c) The proportion of apoptotic cells at 72 h was measured by FACS (n = 2). The amount of cleaved PARP was also analyzed by Western blot. (d) DNA fragmentation was assessed from isolated genomic DNA. The data are shown as the mean ± SD, ***, p < 0.001.

**Figure 4 | Ubb-KD inhibits tumor cell growth in vivo.** (a) PC3 cells (1 × 10⁷) transfected with either control siRNA or Ubb siRNA (8 nM each) were subcutaneously injected into the left and right flanks of nude mice (n = 11). The size of the tumors was measured every 5 days after injection. (b) The size of the tumors at day 40 after injection was compared. (c) The weight of the tumors was measured after dissection (n = 11). The data are shown as the mean ± SD, *, p < 0.05; **, p < 0.01.
TNFα for 10 min (Fig. 6b). However, *Ubb*-KD markedly inhibited this translocation of p65 to the nucleus after the same treatment with TNFα (Fig. 6b). Western blotting of the p65 protein after nuclear/cytoplasmic fractionation was consistent with the immunostaining results (Fig. 6c). Without TNFα treatment, the p65 protein was detected only in the cytoplasmic fraction. After treatment with TNFα, more than 50% of the p65 protein was detected in the nuclear fraction in the control cells, but a substantially lower amount was observed in the *Ubb* siRNA-transfected cells (Fig. 6c).

*Ubb*-KD effectively inhibited the degradation of IκBα as shown in Fig. 6D, presumably by blocking the ubiquitination of IκBα. In addition, we also detected a delay and a decrease in the phosphorylation of IκBα (Fig. 6d), suggesting an inhibition of the ubiquitination of upstream molecules in the NF-κB signaling pathway. Binding of TNFα to its receptor leads to the recruitment of several signaling molecules; one of these signaling molecules, the receptor-interacting protein kinase (RIP1), has emerged as an important target for polyubiquitination. When we analyzed the ubiquitination level of RIP1 after TNFα treatment, we could clearly observe a delayed and decreased ubiquitination of RIP1 in *Ubb* siRNA-transfected cells compared with control cells (Fig. 6d). Taken together, these results indicate that *Ubb*-KD effectively attenuates TNFα–induced NF-κB activation by inhibiting the ubiquitination of upstream signaling molecules as well as IκBα.

**Discussion**

Given that the level of Ub is elevated in many types of tumors, we hypothesized that the level of Ub escalates progressively during a long period of tumorigenesis and that this elevated Ub level then becomes essential for the survival of cancer cells but not for the viability of normal cells. In this study, we demonstrated that the downregulation of Ub by *Ubb*-KD indeed inhibited the proliferation of TNFα.
of several cultured cancer cell lines and was preferentially cytotoxic to MCF7 breast cancer cells over MCF10A normal breast cells. Furthermore, tumor growth of PC3 prostate cancer cells injected subcutaneously into mouse flanks was also inhibited by pretreatment of cancer cells with Ubb siRNA. These results strongly support our hypothesis and the anti-cancer potential of the downregulation of Ub levels through Ubb-KD.

Ub exists in a dynamic state between free and conjugated forms in all eukaryotic cells. If the amounts of free and conjugated Ub are regulated, the downregulation of free Ub by Ubb-KD implicates the limited supply of Ub for continuous as well as signaling-dependent ubiquitination. We also observed that activated Ub, which is linked to the E1 and E2 enzymes through thioester bonds, was similarly decreased when the level of free Ub decreased (Supplementary Fig. 2). Regarding this limited supply of Ub, Ubb-KD may represent an anti-cancer approach that is similar to that involving the inhibition of E1 enzymes. However, the anti-cancer effect of Ubb-KD may be more specific than that of an E1 inhibitor because Ub levels are elevated only in cancer cells and cancer cells are therefore more reliant on the supply of Ub. In this study, we selected Ubb-KD as a tool to downregulate Ub levels because it was reliable with reproducible results. Targeting Ubc always resulted in partial degradation of Ubc mRNA and substantial degradation of Rps27a mRNA (data not shown). Studies of Ubb and Ubc knockout mice also suggested that Ubb-KD might be preferential to Ubc-KD, with fewer side effects.

Evasion of apoptosis plays a key role in cancer cell survival, and thus the induction of apoptosis is one of the most important strategies for anti-cancer therapies. In this study, Ubb-KD effectively induced apoptotic cell death in SH-SY5Y cells, PC3 cells, and HepG2 cells, implying that downregulation of Ub blocks the anti-apoptotic capability of cancer cells. Although the mechanism of how the apoptotic signaling pathways are re-operated by Ubb-KD are not clear, the attenuation of NF-κB activation by Ubb-KD is likely because NF-κB is known to promote the expression of various anti-apoptotic proteins. Apoptotic cell death could also be induced through the stabilization of the tumor suppressor p53 by Ubb-KD, although it is not the case in p53-null mutant PC3 cells. We also observed that Ubb-KD elicited G2/M arrest and apoptosis consecutively in PC3 cells and HepG2 cells, whereas Ubb-KD led to apoptotic cell death without prior G2/M arrest in SH-SY5Y cells. Taken together, our results suggest that an elevated level of Ub is essential to allow most cancer cells to evade apoptosis. Ubb-KD thereby induces apoptosis of cancer cells by re-activation of cell type-dependent apoptotic pathways.
Cancer cells acquire their malignant capabilities through an astounding number of mutations and extensively reprogrammed pathways, which inevitably generate a variety of stresses, including proteotoxic stress. Thus, cancer cells must tolerate these increased stresses through stress-supporting systems such as the heat shock response (HSR) and the Ub system to survive; the HSR and the Ub system are thus considered attractive cancer therapeutic targets. The elevated level of Ub in cancer cells is believed to contribute to the reinforcement of this stress-support system through ubiquitination. Therefore, the downregulation of Ub may lead to stress sensitization by weakening the stress-supporting system, as shown by the inhibition of ubiquitination-dependent substrate protein degradation by Ubb.

In summary, the downregulation of Ubb reduces multiple ubiquitination-mediated pathways and is an effective way to inhibit the proliferation of cancer cells and induce apoptotic cell death, suggesting the downregulation of Ub as a promising anti-cancer therapeutic intervention.

Methods

Cell culture and siRNA transfection. HEK293, HeLa, HepG2, and SH-SY5Y cells were cultured in DMEM (Gibco-BRL, Grand Island, NY, USA) containing 10% FBS (Hyclone, Logan, UT, USA) and 1% penicillin/streptomycin (Gibco-BRL). PC3 and MCF7 cells were cultured in RPMI1640 (Gibco-BRL) and Detroit 551 cells were cultured in MEM Alpha (Gibco-BRL) with the same supplements. MCF10A cells were cultured in DMEM-F12 (Gibco-BRL) supplemented with 5% horse serum (Invitrogen, Carlsbad, CA, USA), 0.5 g/l hydrocortisone (Sigma-Aldrich, St. Louis, MO, USA), 10 μg/ml insulin (Sigma-Aldrich), 20 ng/ml EGF (Peprotech, Rocky Hill, NJ, USA), 100 ng/ml cholera toxin (Sigma-Aldrich), and 1% penicillin/streptomycin. HeLa cells stably expressing HA-xTCR, which were kindly provided by Dr. Cesery Wójcik (Indiana University), and SH-SY5Y cells stably expressing unstable GFP (GFPu) were transfected with siRNA using RNAiMax reagent (Invitrogen) according to the manufacturer’s protocol. siRNA against the polyUb gene (Ubb) was prepared by Invitrogen (Intronovir, Seoul, Korea). The siRNA Negative Control Med GC (Invitrogen, 12935-300) was used as a control. HeLa cells stably expressing HA-xTCR (BIOMOL International, Alliance, Germany) was treated at the final concentration of 10 μM. zVAD-fmk (Sigma-Aldrich) was added to culture medium after transfection at the final concentration of 20 μM.

Reverse transcription polymerase chain reaction analysis. Total RNA was prepared using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer’s instructions. Briefly, cells were harvested and dissolved in 1 ml Trizol reagent, and then 200 μl of chloroform solution was added. After vigorous vortexing, the samples were centrifuged at 12,000 × g at 4°C for 15 min, and the upper aqueous phase was transferred to a new tube. An equal volume of isopropanol (25) was added and the solution was air-dried and dissolved in nuclease-free water. cDNA was generated from total RNA (1 μg of each sample) with the oligo (dT) primer (Promega, Madison, WI, USA) and M-MLV reverse transcriptase (Promega) according to the manufacturer’s instructions. Briefly, cells were cultured in DMEM containing 5% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 0.5 g/l hydrocortisone (Sigma-Aldrich), and 1% penicillin/streptomycin (Gibco-BRL). Cells were transfected with siRNA using RNAiMax reagent (Invitrogen) according to the manufacturer’s protocol. siRNA against the polyUb gene (Ubb) was prepared by Invitrogen (Intronovir, Seoul, Korea). The siRNA Negative Control Med GC (Invitrogen, 12935-300) was used as a control. HeLa cells stably expressing HA-xTCR (BIOMOL International, Alliance, Germany) was treated at the final concentration of 10 μM. zVAD-fmk (Sigma-Aldrich) was added to culture medium after transfection at the final concentration of 20 μM.

Enzyme assays for cell proliferation, apoptosis, cell cycle distribution, and colony formation. Assays for cell proliferation, apoptosis, cell cycle distribution, and colony formation were performed in 24-well plates at a density of 4 × 105 cells per well. Cells were transfected with 5 μg/ml of siRNA or Ubb siRNA. After 72 h, images of the cells were acquired with a CoolSNAP mono CCD camera (Optronics, Los Angeles, CA, USA), and the relative cell proliferation was determined by MTT assay. Cellular DNA contents were assessed via propidium iodide (PI) staining to determine the percentage of apoptotic cells as well as cell cycle distribution. Briefly, the transfected cells were harvested at the indicated times and fixed in 70% ethanol overnight. After washing with PBS, the fixed cells were treated with 0.5 μg/ml of DNP-free Rnase (Sigma-Aldrich) for 20 min at RT and stained with 100 μg/ml of PI in 0.1 M sodium citrate buffer (pH 7.4) at 4°C for 30 min. Cells were analyzed by flow cytometry with an EPICS XE (Beckman Coulter, Fullerton, CA, USA), and cell cycle distribution was determined with the Expo32 program (Beckman Coulter). The sub-G1 population was measured as apoptotic cells. Genomic DNA was also isolated with a G-spin total DNA extraction kit (Intron Biotechnology, Seoul, Korea) according to the manufacturer’s protocol. Apoptosis was visualized by agarose gel electrophoresis and assessed via propidium iodide (PI) staining. A total of 1,000 cells transfected with 20 nM control or Ubb siRNA were seeded in 60 mm dishes. After 7 days, cells were fixed with methanol and stained with 0.5% crystal violet.

Tumor growth study in vivo. PC3 cells were transfected with 8 nM control siRNA or Ubb siRNA for 12 h. After washing the harvested cells with PBS, 106 cells were subcutaneously injected into the left and right flanks of 7-week-old nude mice (NARCALB/c). Tumor size was measured every fifth day for 40 days on a total of 11 nude mice. Tumor volume was calculated using the formula: length × width2/2. For this experiment, male athymic BALB/c mice were obtained from Orient Bio (Icheon, Korea) and maintained under pathogen-free conditions in the animal facility at the Gwangju Institute of Science and Technology (GIST). All the animal experiments were approved by GIST Animal Care and Use committee.

Immunostaining. HeLa cells transfected with 20 nM control siRNA or Ubb siRNA were grown on glass cover slips for 48 h. After treatment with 50 ng/ml TNF-α for 10 min or with 100 ng/ml EGF for 0 h, 0.5 h, and 5 h, the cells were fixed in 4% paraformaldehyde in PBS for 20 min and then permeabilized with 0.2% Triton X-100 in PBS. After fixation, the cells were washed 3 times with PBS and blocked with 1% bovine serum albumin for 20 min. The cells were incubated with primary antibody (anti-p65 or anti-EGFR) overnight at 4°C. The cells were then washed 3 times with PBS. For secondary antibodies, the primary antibody was conjugated with a -sp5 or -EGFR) overnight at 4°C. The cells were then washed 3 times with PBS. Nuclei were labeled with DAPI (Invitrogen) in PBS for 5 min at RT. After a final wash in PBS, the cells were mounted onto slides with anti-guide mounting medium (Molecular Probes Inc., Eugene, OR, USA) and analyzed with an FV1000 confocal laser scanning microscope (Olympus Corporation, Tokyo, Japan). Images were obtained with Fluoview software (Olympus Corporation).

NF-κB-driven luciferase activity assay. A NF-κB(L2)-luciferase reporter plasmid, which was kindly provided by Frank Mercurio (Signal Pharmaceuticals, San Diego, CA, USA), was co-transfected into HeLa cells with control or 5 μg/ml siRNA against p53 (Invitrogen). A heat shock protein 70 (HSP70) β-galactosidase reporter plasmid, which was kindly provided by Robert Modlin (University of California, Los Angeles, CA, USA), was also co-transfected as an internal control. After transfection for 48 h, HeLa cells were treated with TNF-α (50 ng/ml) before assaying luciferase activity. Luciferase and β-galactosidase enzyme activities were determined cell lysate with the Luciferase Assay System and β-galactosidase Enzyme System (Promega) according to the manufacturer’s instructions, and luciferase activity was normalized to β-galactosidase activity to obtain the relative luciferase activity (RLA).
